If further validated in pre-clinical studies, the availability of biosafe inhibitors of CBP/p300 will warrant their combination with AZA to be tested in a clinical trial assessing improvements of the current therapy of high-risk MDS. The gene discussed is EP300; the disease is myelodysplastic syndrome.